P653 MODELING THE IMPACT OF PARTIALLY EFFICACIOUS GONORRHEA VACCINES

¹Shaheen Seedat*, ²Laith Abu-Raddad. ¹Weill Cornell Medicine-Qatar, Infectious Disease Epidemiology Group, Doha, Qatar; ²Weill Cornell Medicine-Qatar, Doha, Qatar

10.1136/sextrans-2019-sti.721

Background Gonorrhea is one of the most common sexually transmitted infections. Current control measures are inadequate and are threatened by the emergence of gonococcal antimicrobial resistance. This emerging challenge calls for a vaccine which will reduce the circulation and transmission of this infection, and thus emergence of drug-resistant strains in the population.

Methods A novel deterministic compartmental mathematical model of the heterosexual transmission of *Neisseria gonorrhoeae* was constructed to assess the impact of a pre-exposure (prophylactic) vaccine.

Results Catch-up vaccination with a prophylactic vaccine introduced in 2020, with vaccine efficacy in reducing susceptibility of 50% and vaccine coverage of 80% at 2030, reduced gonorrhea prevalence by 29% by 2030, 34% by 2040, and 37% by 2050. The number of vaccinations needed to avert one infection was 31 in 2030, 24 in 2040, and 13 in 2050. Through age group prioritization, the number of vaccinations needed to avert one infection (in 2030) ranged from 24 for the 15–19 years age group, to 50 for the 45–49 age group. Through risk group prioritization (also in 2030), prioritizing the highest sexual risk group (such as female sex workers) was most effective with only 1 vaccination needed per infection averted. Meanwhile, for the lowest sexual risk group (general population), 110 vaccinations were needed per infection averted.

Conclusion Even a partially efficacious gonorrhea vaccine can considerably reduce the prevalence of infection. Vaccine effectiveness is optimized by targeting high sexual risk groups and young individuals.

Disclosure No significant relationships.

P654 CLONAL SPREAD OF AZITHROMYCIN RESISTANT NEISSERIA GONORRHOEAE IN CANADA, 2014–2017

¹Irene Martin*, ¹Pam Sawatzky, ²Brigitte Lefebvre, ³Vanessa Allen, ⁴Prenilla Naidu, ⁵Linda Hoang, ⁶Jessica Minion, ⁷Dauid Haldane, ⁸Mike Mulvey. ¹Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Canada; ²Laboratoire Santé Publique du Québec, Montréal, Canada; ³Public Health Ontario, Toronto, Canada; ⁴Provincial Laboratory for Public Health, Edmonton, Canada; ⁵British Columbia Centres for Disease Control, Vancouver, Canada; ⁶Saskatchewan Health Authority, Regina Qu'appelle Health Region, Regina, Canada; ⁷Provincial Public Health Laboratory Network of Nova Scotia, Halifax, Canada; ⁸Public Health Agency of Canada, Winnipeg, Canada

10.1136/sextrans-2019-sti.722

Background *Neisseria gonorrhoeae* have acquired resistance to many antimicrobials including third generation cephalosporins and azithromycin, the current co-therapy recommended by the Canadian STI guidelines for gonorrhea treatment. Resistance to azithromycin and molecular sequence types were determined for *N. gonorrhoeae* circulating in Canada.

Methods From 2014–2017, *N. gonorrhoeae* isolates and data collected by Canadian provincial public health laboratories was submitted to the National Microbiology Laboratory (N=12,776) for *N. gonorrhoeae* multi-antigen sequence typing (NG-MAST) and azithromycin MIC determination (resistance

MIC≥2.0 mg/L) by agar dilution, as described by the Clinical Laboratory Standards Institute.

Results Azithromycin resistance was identified in 3.3% (127/3,809), 4.7% (198/4,190), 7.2% (326/4,538) and 11.6% (616/5,290) of *N. gonorrhoeae* in 2014, 2015, 2016 and 2017, respectively, a significant increase between 2014–2017 ($p<0.001$). MICs ranged from 2–≥256 mg/L. The most common sequence types identified in the azithromycin resistant isolates include: 2014; ST10451 (n=40), ST10567 (n=38) and ST11765 (n=10); 2015; ST12302 (n=110), ST10451 (n=34) and ST9047 (n=23); 2016: ST12302 (n=240), ST15750 (n=27) and ST10451 (n=10); 2017; ST12302 (n=375), ST14698 (n=119) and ST15750 (n=17). ST12302 was newly recognized in 2015 and identified in only two provinces, Quebec and Ontario, but spread to Alberta (n=10) and British Columbia (n=16) in 2017. ST12302 is associated with low-level azithromycin resistance (MIC=2 mg/L). ST10451 emerged in 2014 in Quebec, Ontario and Alberta and was also identified in 2015–2017. ST10451 is related to ST1407 (differing by 1 bp) which is an internationally-recognized epidemic strain, harboring cephalosporin resistance.

Conclusion Azithromycin resistance in *N. gonorrhoeae* is established and spreading in Canada, increasing significantly between 2014 and 2017. This exceeds the 5% level at which the WHO states an antimicrobial should be reviewed as an appropriate treatment. Continued surveillance of antimicrobial susceptibilities and sequence types of *N. gonorrhoeae* is necessary to identify clusters, inform treatment guidelines and mitigate the impact of resistant gonorrhea.

Disclosure No significant relationships.

P655 MOLECULAR EPIDEMIOLOGY ASSOCIATED WITH RESISTANCE IN NEISSERIA GONORRHOEAE ISOLATES FROM SOUTH BRAZIL DURING 2008–2016

¹Lisléia Goffetto, ¹Marcos Schömer, ²Thais Santos, ¹Jéssica Martins, ¹Hanallydia Machado, ¹Felipe De Rocco, ¹Mara Scheffer, ²Emanuelle Da Silva, ²Nina Tobouti, ²Cássia Zoccoli, ¹Maria Bazzo*. ¹Federal University of Santa Catarina, Florianópolis, Brazil; ²Santa Luzia Medical Laboratory, Florianópolis, Brazil

10.1136/sextrans-2019-sti.723

Background *Neisseria gonorrhoeae* (NG) has an extraordinary ability to develop resistance to all antimicrobials used for its treatment. This study analysed molecular determinants of antimicrobial resistance and NG-MAST of 153 NG isolates collected at Florianopolis metropolitan area during 2008–2016.

Methods Minimal Inhibitory Concentration (MIC) was determined by agar dilution and the molecular epidemiology was evaluated by NG-MAST.

Results Resistance was observed to penicillin (PEN) (26.1%), tetracycline (TET) (41.2%), ciprofloxacin (CIP) (52.3%) and azithromycin (AZT) (5.2%). All isolates were susceptible to cefixime (CFX) and ceftriaxone (CRO). However, 8.5% of isolates had MIC=0.125 mg/L for CFX, one log below the resistance cut-off point (EUCAST). β -lactamase production was detected in 12.4% of isolates and one of them carried the *bla*_{TEM-135} allele. The American or Dutch *tetM* gene were carried by 5.2% of the isolates. Mutations in the QRDR were observed in 87.5% of isolates resistant to CIP. NG-MAST showed 64 different sequence types (STs), including 19 novel STs. ST225, ST2992, ST1582, ST338, ST1407, ST2202 and ST6827 were most prevalent. G225 genogroup was associated with resistance to CIP ($p<0.001$), PEN ($p=0.016$) and TET